PACT logo

For Clinicians

Over the past decade high quality trials have transformed treatment approaches for patients with PF both by ensuring patients are not exposed to potentially harmful treatments and by supporting access to treatments with proven efficacy. Find out more in the Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia, here.

Enrollment in clinical trails is now considered standard of care for patients with pulmonary fibrosis, much as it is for patients with cancer. Clinicians – be they PF ‘experts’ or not – have a vital role to play in encouraging enrollment in high quality clinical trials, especially since PF is an uncommon disease impeding recruitment to very large trials. Below are links to Pulmonary Fibrosis trials currently recruiting in Australasia.

Trial

Title

Status

More Information

Isabela 1&2 A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis Recruiting

Trial Summary

Study ID: NCT0371l-162
Trail1 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD) Recruiting Trial Summary Study ID: NCT02808871  
PFOX PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial Recruiting Trial Summary Study Id: NCT03737409
COLDICE Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease allianCE Study completed

Trial Summary

Study Id: ACTRN12615000718549
ATLAS A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis Recruiting

Trial Summary

Study Id: ACTRN12618001838202
HIIT High intensity interval training in fibrotic interstitial lung disease Not yet recruiting

Trial Summary

Study Id: NCT03800914
SPIRIT A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Recruiting

Trial Summary

Study ID: NCT03573505
GRIPF Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF) Recruiting

Trial Summary

Not applicable
HHF-ILD Handheld fan for breathlessness in interstitial lung disease Recruiting

Trial Summary

Study Id: ACTRN12618001838202